Erschienen in:
01.09.2007 | Melanomas
Can Completion Lymph Node Dissection Be Avoided for a Positive Sentinel Node in Melanoma?
verfasst von:
Donald L. Morton, MD, Randall P. Scheri, MD, Charles M. Balch, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 9/2007
Einloggen, um Zugang zu erhalten
Excerpt
Sentinel node biopsy (SNB) in melanoma was developed as a minimally invasive technique to identify the 20% of patients who have occult lymph node metastases and therefore could benefit from completion lymph node dissection (CLND). Recently published interim results from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I) have validated the accuracy and reliability of SNB in melanoma.
1,
2 Interestingly, results revealed that nearly 80–90% of patients who underwent CLND after a positive SNB had no other lymph node metastases; the percentage varies with the thickness of the primary melanoma and the amount of tumor in the sentinel node (SN).
3,
4 Does this mean that CLND may not be indicated for all patients with SN metastasis? Many studies have attempted to answer this question, but as yet none have identified a reliable and accurate method to distinguish patients whose SN metastasis does not require CLND. …
